日前,华领医药发布公告显示,其全资附属公司华领医药技术(上海)有限公司向拜耳发出书面通知,表示有意从 2025 年 1 月 1 日起,将本公司开发的用于治疗 2 型糖尿病的首创葡萄糖激酶激活剂华堂宁®(多格列艾汀片)在中国的商业化责任过渡至本公司。 华领医药方面称,“从公告日期起到终止生效日期为止,拜耳与本公司将继续履行协议项下的义务,并承诺启动一个友好的、以患者为中心的过渡计划。为支持华堂宁®...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.